About 2N Pharma and the Project

2N Pharma is dedicated to understanding and fighting ALS by investigating the underlying causes of disease progression. Their work has already produced promising results. Dr. John Nieland, Co-founder and Chief Scientific Officer of 2N Pharma, shares: “We are very encouraged by the initial results that support 2N Pharma’s hypothesis that mitochondrial metabolic imbalances are a key driver of ALS disease progression. We have demonstrated that mice with ALS treated with our experimental drug survive significantly longer than those receiving a placebo. Additionally, we have made substantial progress in identifying new biomarkers for ALS diagnosis, and we have shown that people with downregulated lipid metabolism are protected against brain diseases like ALS, MS, and Parkinson’s, a finding we have confirmed in mouse models.”

Collaboration with Ambolt

“A key element of this project is our close collaboration with Ambolt AI. 2N Pharma brought Ambolt on board for their expertise in advanced data analysis and AI, which are essential for managing the large datasets generated by our research,” explains Dr. Steinunn Helgudottir, Head of Biology at 2N Pharma. “Traditionally, we have collaborated with specialists in disease biology or clinicians who work directly with patients. However, with the massive amounts of data we are now producing and the need to identify complex correlations, we decided to partner with a company focused on AI—and it has truly been transformative. Ambolt’s data scientists have provided the expertise needed to build a robust data analysis engine, which is already beginning to yield new insights into this extremely complex disease.”

Ambolt’s consultancy and deep expertise have been pivotal in uncovering previously hidden correlations within the data. Dr. Helgudottir adds, “It is evident that AI will play a significant role across many aspects of our lives, including drug development. We are thrilled to work with such a respected company in this field.”

Looking Ahead

With these promising results and continued support from key partners like Ambolt, 2N Pharma is optimistic about the future of developing new treatments for ALS. The combination of cutting-edge biotechnology and Ambolt’s AI-driven data analysis is opening new possibilities for understanding and fighting this devastating disease.